Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

769 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials.
Goetz MP, Okera M, Wildiers H, Campone M, Grischke EM, Manso L, André VAM, Chouaki N, San Antonio B, Toi M, Sledge GW Jr. Goetz MP, et al. Among authors: toi m. Breast Cancer Res Treat. 2021 Apr;186(2):417-428. doi: 10.1007/s10549-020-06029-y. Epub 2021 Jan 3. Breast Cancer Res Treat. 2021. PMID: 33392835 Free PMC article. Clinical Trial.
Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage breast carcinoma.
Iwata H, Nakamura S, Toi M, Shin E, Masuda N, Ohno S, Takatsuka Y, Hisamatsu K, Yamazaki K, Kusama M, Kaise H, Sato Y, Kuroi K, Akiyama F, Tsuda H, Kurosumi M; Japan Breast Cancer Research Group. Iwata H, et al. Among authors: toi m. Breast Cancer. 2005;12(2):99-103. doi: 10.2325/jbcs.12.99. Breast Cancer. 2005. PMID: 15858439 Free article. Clinical Trial.
Who benefits from hormone therapy?
Toi M, Iino Y. Toi M, et al. Breast Cancer. 2006;13(2):117-22. doi: 10.2325/jbcs.13.117. Breast Cancer. 2006. PMID: 16755104 Free article. Review.
Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival.
Toi M, Nakamura S, Kuroi K, Iwata H, Ohno S, Masuda N, Kusama M, Yamazaki K, Hisamatsu K, Sato Y, Kashiwaba M, Kaise H, Kurosumi M, Tsuda H, Akiyama F, Ohashi Y, Takatsuka Y; Japan Breast Cancer Research Group (JBCRG). Toi M, et al. Breast Cancer Res Treat. 2008 Aug;110(3):531-9. doi: 10.1007/s10549-007-9744-z. Epub 2007 Sep 19. Breast Cancer Res Treat. 2008. PMID: 17879158 Clinical Trial.
[Breast and endocrine tumor].
Toi M. Toi M. Gan To Kagaku Ryoho. 2008 Dec;35(13):2338. Gan To Kagaku Ryoho. 2008. PMID: 19117100 Japanese. No abstract available.
[Treatment for breast cancer and endocrine neoplasm].
Takada M, Ishiguro H, Toi M. Takada M, et al. Among authors: toi m. Gan To Kagaku Ryoho. 2008 Dec;35(13):2344-50. Gan To Kagaku Ryoho. 2008. PMID: 19117102 Japanese. No abstract available.
The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype.
Aogi K, Yoshida M, Sagara Y, Kamigaki S, Okazaki M, Funai J, Fujimoto T, Toi M, Saeki T, Takashima S. Aogi K, et al. Among authors: toi m. Cancer Chemother Pharmacol. 2011 May;67(5):1007-15. doi: 10.1007/s00280-010-1390-1. Epub 2010 Jul 14. Cancer Chemother Pharmacol. 2011. PMID: 20628744 Clinical Trial.
769 results